Product Description
Mechanisms of Action: G-CSF
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin
Phase 3: Acute Respiratory Distress Syndrome|Neutropenia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin
Phase 2: Lymphoma|Neutropenia|Multiple Myeloma|Sarcoma, Ewing|Rhabdomyosarcoma
Phase 1: Sarcoma, Ewing|Rhabdomyosarcoma|Pregnancy Outcomes|Neutropenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2015-000087-34 | P2 |
Completed |
Rhabdomyosarcoma|Sarcoma, Ewing|Neutropenia |
2019-01-08 |
|
| SHEBA-14-1852-AN-CTIL | P2 |
Unknown status |
Lymphoma|Multiple Myeloma |
2018-07-01 |
|
| AVOID Neutropenia | P3 |
Completed |
Lymphoma, Non-Hodgkin|Acute Respiratory Distress Syndrome|Lymphoma, B-Cell |
2018-04-24 |
|
| 2014-005096-85 | P4 |
Completed |
Non-Small-Cell Lung Cancer |
2018-02-09 |